VANCOUVER, BC / ACCESSWIRE / November 18, 2021 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce the appointment of Professor Michael Catt as Senior Scientific Adviser to the Company.
Professor Catt is an expert in in-vitro diagnostic development for human health and wellbeing. In a storied career, he has held senior development roles at some of the world's leading in-vitro diagnostic and human wellness companies. While at Unilever, Professor Catt served as Head of Research for Women's Health at Unipath and was a co-originator of novel consumer health and wellbeing products marketed under the Clearblue and Clearplan brands, now part of Swiss Precision Diagnostics. Subsequent roles with both multinational and diverse technology start-ups have similarly led to further contributions to novel health and wellbeing products and services. Professor Catt co-created Unilever's ‘Healthy Ageing' programme, directly leading to his appointment as a Professor of Practice at the Institute for Ageing and Health, Newcastle University and his subsequent contribution to the establishment of the UK's new National Innovation Centre for Ageing, serving as Director and as Co-Principal Investigator for the UK National Institute of Health Research Innovation Observatory. Professor Catt is now Emeritus Professor at Newcastle University Population Health Sciences Institute and holds a prestigious Turing fellowship.
Gemina began working with Professor Catt in November 2020, at which time Professor Catt, in support of Paragreen Associates, undertook a technical review of the Company's surface chemistry platform. After the conclusion of that review process, Professor Catt continued to work with Gemina on an advisory basis - a role that has already proved immensely productive, as the Company has evolved successive generations of its platform.
"The Company is immensely fortunate to work with someone of Mike's stature," stated Rob Greene, Gemina's co-founder and CTO. "Mike brings to Gemina his internationally significant expertise in the rapid testing domain, and a global network of potential partners in academia, industry and government. It's fair to say that Mike could devote his talents to any number of opportunities, so it is with great pleasure that we're able to formalise his role within Gemina. It is very exciting looking forward to what we will accomplish working together."
In conjunction with the appointment, pursuant to the Company's stock option plan, Gemina has granted options to acquire 100,000 common shares of the Company, at an exercise price of $0.45 cents per common share exercisable for a term of 5 years from the date of grant, subject to vesting requirements.
On Behalf of the Board of Directors
John Davies
CEO
Gemina Laboratories Ltd.
About Gemina Laboratories Ltd.
Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. Additional information on the Company can be found at www.geminalabs.com.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this Release.
Forward Looking Statements
This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Such statements include statements regarding the anticipated terms of any proposed transaction or engagement. Information and statements which are not purely historical fact are forward-looking statements. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Furthermore, the Company is presently unable to fully quantify the impact that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may affect planned or assumed performance moving forward. As such, any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.
For more information regrading the Company, please contact:
James Tansey
Telephone: 604-562-4546
Email: [email protected]
SOURCE: Gemina Laboratories Ltd.